Maxim Reaffirms Buy On Synthetic Bio Ahead Of Trimesta Presentation
In a research note released yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (NYSE:SYN) with a $6 price target ahead of SYN’s presentation of their Trimesta phase II data.
Kolbert wrote, “Earlier this summer we performed a side-by-side comparison of Trimesta and RPC-1063. RPC-1063 is an advanced product from Receptos (NASDAQ:RCPT) indicated for the treatment of relapsing MS. We found that Trimesta looks quite good.” The analyst continued, “We believe that if one examines the totality of the data, Trimesta can be an approved drug that impacts MS symptoms as well as disease progression (brain lesions and cognition).”
Kolbert added, “The phase II, double-blinded, placebo-controlled trial randomized 158 women with RRMS at 16 sites across the U.S. The data showed that Trimesta plus Copaxone demonstrated a reduced annualized relapse rate (47%, p=0.0326 statically ignorant) and improved cognitive function at 12 months of treatment as compared to placebo plus Copaxone. In addition, a significant improvement in cognitive function was observed at 12 months as measured by Paced Auditory Serial Addition Test (PASAT) scores (see the exhibits on page 2). After 24 months of treatment, the reduction in relapse rates persisted in favor of the Trimesta plus Copaxone treatment group compared to the Copaxone plus placebo group (32%). Both treatment groups exhibited improvement in measures of cognitive function at 24 months. Treatment was safe and well tolerated with no evidence of adverse effects on the breast or uterus.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 14.1% and a 56.7% success rate. Kolbert has a 20.3% average return when recommending SYN, and is ranked #186 out of 3295 analysts.